Sartorius Supports ABL Europe in Viral Vector GMP Capacity Expansion

March 19, 2018

Sartorius has delivered to ABL’s Strasbourg facility, a GMP viral vector manufacturing package solution that includes single-use bioreactors and an automation platform for normal flow filtration, tangential filtration, and mixing.

Sartorius Stedim Biotech (SSB), a supplier for the biopharmaceutical industry, announced on Mar. 16, 2018 that it has been selected by ABL Europe as its primary supplier of single-use systems. Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg, France. ABL Europe provides dedicated viral vector GMP manufacturing services for oncolytic, vaccine, and gene therapy projects in all stages of clinical development through to commercial launch.

SSB has delivered a GMP viral vector manufacturing package solution that includes single-use bioreactors and an automation platform for normal flow filtration, tangential filtration, and mixing. These systems have been installed at the Strasbourg facility, which is now in the process of manufacturing batches of viral vector products for ABL’s clients. SSB’s end-to-end process solutions in single-use format have helped ABL expand its existing drug substance capacity, with a fully disposable manufacturing capability for different viral vector product types produced in non-adherent cell lines.

Source: Sartorius Stedim Biotech